WO2003083065A3 - Improved methods for achieving expression from alphavirus vectors - Google Patents

Improved methods for achieving expression from alphavirus vectors Download PDF

Info

Publication number
WO2003083065A3
WO2003083065A3 PCT/US2003/009121 US0309121W WO03083065A3 WO 2003083065 A3 WO2003083065 A3 WO 2003083065A3 US 0309121 W US0309121 W US 0309121W WO 03083065 A3 WO03083065 A3 WO 03083065A3
Authority
WO
WIPO (PCT)
Prior art keywords
alphavirus
methods
vivo
cells
reagents
Prior art date
Application number
PCT/US2003/009121
Other languages
French (fr)
Other versions
WO2003083065A2 (en
Inventor
Kate D Ryman
William B Klimstra
Robert E Johnston
Laura J White
Jiagang Wang
Original Assignee
Univ North Carolina
Kate D Ryman
William B Klimstra
Robert E Johnston
Laura J White
Jiagang Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Kate D Ryman, William B Klimstra, Robert E Johnston, Laura J White, Jiagang Wang filed Critical Univ North Carolina
Priority to AU2003222068A priority Critical patent/AU2003222068A1/en
Publication of WO2003083065A2 publication Critical patent/WO2003083065A2/en
Publication of WO2003083065A3 publication Critical patent/WO2003083065A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides methods and reagents for enhancing alphavirus replication and gene expression in target cells by manipulating the PKR and/or IFN induced antiviral pathways present in the cell. The methods may also be practiced to expand alphavirus tropism to cells that are typically non-permissive, or only poorly so, for alphavirus replication and infection. The methods may be practiced in vitro, ex vivo or in vivo, for example, for the purposes of producing an alphavirus vector stock or a protein of interest in vitro, or for achieving immunogenic or therapeutic effects in a subject in vivo. Also provided are reagents (helper cells, nucleic acid constructs, helper sequences, alphavirus vectors, and the like) for practicing the methods of the invention.
PCT/US2003/009121 2002-03-25 2003-03-25 Improved methods for achieving expression from alphavirus vectors WO2003083065A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003222068A AU2003222068A1 (en) 2002-03-25 2003-03-25 Improved methods for achieving expression from alphavirus vectors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36789302P 2002-03-25 2002-03-25
US36777602P 2002-03-25 2002-03-25
US60/367,893 2002-03-25
US60/367,776 2002-03-25

Publications (2)

Publication Number Publication Date
WO2003083065A2 WO2003083065A2 (en) 2003-10-09
WO2003083065A3 true WO2003083065A3 (en) 2004-07-29

Family

ID=28678198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009121 WO2003083065A2 (en) 2002-03-25 2003-03-25 Improved methods for achieving expression from alphavirus vectors

Country Status (2)

Country Link
AU (1) AU2003222068A1 (en)
WO (1) WO2003083065A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
ATE432285T1 (en) 2003-07-11 2009-06-15 Alphavax Inc CYTOMEGALOVIRUS VACCINES BASED ON ALPHAVIRUS
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
CA2597921A1 (en) 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
ES2304880B1 (en) * 2007-04-03 2009-10-27 Proyecto De Biomedicina Cima, S.L. USE OF A MUTED VIRAL VECTOR FOR THE IN VITRO GENERATION OF STABLE CELLULAR LINES.
PL2947149T3 (en) 2007-06-21 2018-09-28 Alphavax, Inc. Alphavirus replicon particles for use in vaccination
GB201310432D0 (en) * 2013-06-12 2013-07-24 Univ St Andrews Virus Production
WO2015118146A1 (en) 2014-02-10 2015-08-13 Univercells Nv System, apparatus and method for biomolecules production
US20210275615A1 (en) * 2018-09-14 2021-09-09 Laura Evgin Materials and methods for treatment with oncolytic viruses and modified car t cells
CN112912507A (en) * 2018-11-07 2021-06-04 磨石肿瘤生物技术公司 Alphavirus novel antigen vector and interferon inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232035A1 (en) * 1993-09-15 2003-12-18 Dubensky Thomas W. Eukaryotic layered vector initiation systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232035A1 (en) * 1993-09-15 2003-12-18 Dubensky Thomas W. Eukaryotic layered vector initiation systems

Also Published As

Publication number Publication date
AU2003222068A1 (en) 2003-10-13
WO2003083065A2 (en) 2003-10-09
AU2003222068A8 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
Quabius et al. Synthetic mRNAs for manipulating cellular phenotypes: an overview
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
GB2556276A (en) Engineered crispr-CAS9 compositions and methods of use
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
WO2006096815A3 (en) NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
WO2004022716A3 (en) Recombinatant mutants of rhabdovirus and methods of use thereof
PH12012500758A1 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
WO2003083065A3 (en) Improved methods for achieving expression from alphavirus vectors
EP1712243A4 (en) Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines
DE60041280D1 (en) CHIMERIC HUMAN CATTLE RESPIRATORY SYNCYTIAL VIRUS VACCINES
WO2001083774A3 (en) Novel mutated form of arginine deiminase
WO2004053103A3 (en) METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
Santos et al. Structure–activity relationships for dipeptide prodrugs of acyclovir: Implications for prodrug design
WO2006002627A3 (en) Chicken deoxycytidine and deoxyadenosine kinase enzymes and their use
WO2004018630A3 (en) Recombinant double-stranded rna phages and uses thereof
WO2008127450A3 (en) Linear expression cassette vaccines
WO2007089950A3 (en) Preparations of growth hormone
DE60002603D1 (en) PHOSPHORUS-CONTAINING DENDRIMERS AS TRANSFECTION AGENTS
MX2021003345A (en) Nucleic acids for cell recognition and integration.
WO2001025398A3 (en) Process for inducing functional tolerance to gene transfer products
AU2001231675A1 (en) Regulatory sequence for the specific expression in dendritic cells and uses thereof
ATE315406T1 (en) SEMI-ALLOGENE ANTITUMOR VACCINE WITH HLA-HAPLO-IDENTIAL ANTIGEN-PRESENTING CELLS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP